Review of NICE Technology Appraisal Guidance No. 23; The use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)

Proposal to defer the review

The planned date for review of the above guidance was February 2011.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

The Institute has carried out a search for information relevant to this appraisal, and has found that to the best of its knowledge, no new evidence has been published that would have a material effect on the original guidance.  

Consequently we propose that the decision to review TA23 is deferred and will be taken alongside the decision to review TA121; Carmustine implants and temozolomide for the treatment of newly diagnosed high grade glioma, so that the option to combine the review of the two appraisals can be considered. The decision to review TA121 is expected to take place in 2015. 

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.  Please see appendix A for a full list of the organisations we have contacted.

March 2011

Appendices